Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis: a study of 504 cases
- PMID: 7506644
- DOI: 10.1007/BF02090056
Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis: a study of 504 cases
Abstract
The incidence of posttransfusion hepatitis and "fulminant" hepatitis was investigated by a plan devised at our hospital in December 1982. Of 2959 blood recipients between January 1982 and December 1988, 504 (22.5%) developed posttransfusion hepatitis, with a mean transfusion volume of 10.2 units. Of the 504 cases of posttransfusion hepatitis, "icteric" (T-Bil > 2.0 mg/dl) and "overt icteric" hepatitis (T-Bil > 5.0 mg-dl) developed in 111 cases (22.0%) and 28 cases (5.6%), respectively. Of the 28 overt icteric hepatitis cases, 13 (2.8%) were thought to be true overt icteric posttransfusion hepatitis because the icterus was caused by other reasons in the other 15 cases (seven neonatal jaundice, four hemolytic anemia, one radiation hepatitis, one halothane-induced hepatitis; two other cases were excluded because chronic liver disease was diagnosed by imaging procedures despite serum ALTs in the normal range before transfusion). The anti-HCV serostatus was investigated in five of the 13 true overt icteric posttransfusion hepatitis patients using blood specimens taken 180 days or more following the onset of posttransfusion hepatitis. Anti-HCV seroconversion occurred in three of the five cases (60%). HCV seroconversions were not seen in the cases in which the icterus was due to other reasons.
Similar articles
-
Low incidence of non-A, non-B post-transfusion hepatitis in London confirmed by hepatitis C virus serology.Lancet. 1991 Mar 30;337(8744):753-7. doi: 10.1016/0140-6736(91)91370-a. Lancet. 1991. PMID: 1672391 Clinical Trial.
-
Antibodies to hepatitis C virus in prospectively followed patients with posttransfusion hepatitis.J Infect Dis. 1991 Jun;163(6):1354-7. doi: 10.1093/infdis/163.6.1354. J Infect Dis. 1991. PMID: 1645386
-
Posttransfusion hepatitis in Japan.Vox Sang. 1992;62(3):156-64. doi: 10.1111/j.1423-0410.1992.tb01190.x. Vox Sang. 1992. PMID: 1609517
-
Impacts of blood screening on the incidence of posttransfusion hepatitis C in Japan.Curr Stud Hematol Blood Transfus. 1994;(61):182-94. doi: 10.1159/000423275. Curr Stud Hematol Blood Transfus. 1994. PMID: 7525155 Review. No abstract available.
-
Post-transfusion NANBH in the light of a test for anti-HCV.Blood Rev. 1991 Dec;5(4):234-9. doi: 10.1016/0268-960x(91)90014-4. Blood Rev. 1991. PMID: 1664267 Review.
Cited by
-
Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.Hepatol Int. 2015 Oct;9(4):486-507. doi: 10.1007/s12072-015-9630-4. Epub 2015 May 5. Hepatol Int. 2015. PMID: 25941137 Review.
-
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.Virol J. 2025 Aug 11;22(1):274. doi: 10.1186/s12985-025-02907-3. Virol J. 2025. PMID: 40790753 Free PMC article. Review.
-
Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare.Viruses. 2023 Jan 8;15(1):183. doi: 10.3390/v15010183. Viruses. 2023. PMID: 36680223 Free PMC article. Review.
-
Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors.Hepatol Int. 2025 Apr 8. doi: 10.1007/s12072-025-10825-3. Online ahead of print. Hepatol Int. 2025. PMID: 40198524
-
Acute hepatitis C virus infection: clinical update and remaining challenges.Clin Mol Hepatol. 2023 Jul;29(3):623-642. doi: 10.3350/cmh.2022.0349. Epub 2023 Feb 20. Clin Mol Hepatol. 2023. PMID: 36800699 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical